Maria J. Donde

Maria J. Donde

Auto-generated profile, based on publicly available information

Maria J. Donde

Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
JTJake R. Thomas
Jake R. Thomas
AAAnna Appios
Anna Appios
XZXiaohui Zhao
Xiaohui Zhao
RDRoksana Dutkiewicz
Roksana Dutkiewicz
MDMaria Donde
Maria Donde
NMNaomi McGovern
Naomi McGovern
Hofbauer cells (HBCs) are a population of macrophages found in high abundance within the stroma of the first-trimester human placenta. HBCs are the only fetal immune cell population within the stroma of healthy placenta. However, the functional properties of these cells are poorly described. Aligning with their predicted origin via primitive hematopoiesis, we find that HBCs are transcriptionally similar to yolk sac macrophages. Phenotypically, HBCs can be identified as HLA-DR−FOLR2+ macrophages. We identify a number of factors that HBCs secrete (including OPN and MMP-9) that could affect placental angiogenesis and remodeling. We determine that HBCs have the capacity to play a defensive role, where they are responsive to Toll-like receptor stimulation and are microbicidal. Finally, we also identify a population of placenta-associated maternal macrophages (PAMM1a) that adhere to the placental surface and express factors, such as fibronectin, that may aid in repair.

5 September 2022 in Nature Chemistry
Verified
Journal Article
Closed access
PDF file
ATAlexander I. Taylor
Alexander I. Taylor
CWChristopher J. K. Wan
Christopher J. K. Wan
MDMaria J. Donde
Maria J. Donde
SPSew Peak-Chew
Sew Peak-Chew
PHPhilipp Holliger
Philipp Holliger

24 September 2022 in Communications Biology
Verified
Journal Article
Open access
PDF file
MDMaria J. Donde
Maria J. Donde
ARAdam M. Rochussen
Adam M. Rochussen
SKSaksham Kapoor
Saksham Kapoor
ATAlexander I. Taylor
Alexander I. Taylor
Non-coding RNAs (ncRNAs) offer a wealth of therapeutic targets for a range of diseases. However, secondary structures and high similarity within sequence families make specific knockdown challenging. Here, we engineer a series of artificial oligonucleotide enzymes (XNAzymes) composed of 2’-deoxy-2’-fluoro-β-D-arabino nucleic acid (FANA) that specifically or preferentially cleave individual ncRNA family members under quasi-physiological conditions, including members of the classic microRNA cluster miR-17~92 (oncomiR-1) and the Y RNA hY5. We demonstrate self-assembly of three anti-miR XNAzymes into a biostable catalytic XNA nanostructure, which targets the cancer-associated microRNAs miR-17, miR-20a and miR-21. Our results provide a starting point for the development of XNAzymes as a platform technology for precision knockdown of specific non-coding RNAs, with the potential to reduce off-target effects compared with other nucleic acid technologies.

16 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
PGPehuén Pereyra Gerber
Pehuén Pereyra Gerber
MDMaria J. Donde
Maria J. Donde
NMNicholas Matheson
Nicholas Matheson
ATAlexander I. Taylor
Alexander I. Taylor
The unprecedented emergence and spread of SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic, underscores the need for diagnostic and therapeutic technologies that can be rapidly tailored to novel threats. Here, we show that site-specific RNA endonuclease XNAzymes – artificial catalysts composed of single-stranded synthetic xeno-nucleic acid oligonucleotides (in this case 2’-deoxy-2’-fluoro-β-D-arabino nucleic acid) – may be designed, synthesised and screened within days, enabling the discovery of a range of enzymes targeting SARS-CoV-2 ORF1ab, ORF7b, spike- and nucleocapsid-encoding RNA. Three of these are further engineered to self-assemble into a catalytic nanostructure with enhanced biostability. This XNA nanostructure is capable of cleaving genomic SARS-CoV-2 RNA under physiological conditions, and when transfected into cells inhibits infection with authentic SARS-CoV-2 virus by RNA knockdown. These results demonstrate the potential of XNAzymes to provide a platform for the rapid generation of antiviral reagents.